Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EPS (Weighted Average and Diluted) (2022 - 2025)

Stoke Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.97 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 470.59% year-over-year to -$0.97; the TTM value through Dec 2025 reached -$0.12, up 92.81%, while the annual FY2025 figure was -$0.12, 92.73% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.97 at Stoke Therapeutics, down from -$0.65 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.9 in Q1 2025 and troughed at -$0.97 in Q4 2025.
  • A 4-year average of -$0.42 and a median of -$0.58 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 433.33% in 2025 and fell as far as 470.59% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.65 in 2022, then rose by 7.69% to -$0.6 in 2023, then skyrocketed by 71.67% to -$0.17 in 2024, then tumbled by 470.59% to -$0.97 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for STOK at -$0.97 in Q4 2025, -$0.65 in Q3 2025, and -$0.4 in Q2 2025.